Although anti-TNF-Alfa, interleukin-17 (IL-17), and interleukin-23 (IL-23) blockade therapies are the biologic disease-modifying anti-rheumatic drugs (bDMARDs) approved for PsA, some reports emphasize up-regulation of IL-1 in the skin and synovium of patients with psoriasis and PsA [10] and therefore Anakinra was used in small cohorts to treat PsA with success [10,11]. The gene discussed is IL17A; the disease is psoriasis.